Skin Substitute Fraud Whistleblower

A skin substitute fraud whistleblower is a person who reports fraudulent billing of Medicare and other federal health care programs for skin substitutes — bioengineered wound coverings, including amniotic membrane allografts made from human placental tissue — under the federal False Claims Act. The statute, 31 U.S.C. §§ 3729-3731, allows a private person to file a qui tam lawsuit in the name of the United States government and, if the case leads to a recovery, to receive a share of the proceeds under 31 U.S.C. § 3730(d). Wound-care nurses, nurse practitioners, sales representatives for graft companies, and billers at mobile wound-care practices are often the first people positioned to see it.

Wound care fraud is now one of the Justice Department’s most visible enforcement priorities and one of the newest forms of Medicare fraud. In the 2025 National Health Care Fraud Takedown, the department charged seven defendants, including five medical professionals, in connection with approximately $1.1 billion in fraudulent claims to Medicare and other health care benefit programs for amniotic wound allografts. The 2026 National Health Care Fraud Takedown followed with charges against 11 defendants across six districts over billions of dollars in fraudulent amniotic allograft claims — including one scheme in which providers billed Medicare over $4 billion for a single company’s allografts between approximately December 2021 and June 2024.

Why Federal Enforcement Turned to Wound Care and Skin Substitutes

The spending data explains the scrutiny. According to the CMS fact sheet for the CY 2026 Medicare Physician Fee Schedule final rule, Medicare Part B spending on skin substitutes rose from $252 million in 2019 to over $10 billion in 2024 — a nearly 40-fold increase that CMS attributes mostly to increases in payment rates and launch prices for the products.

Prosecutors noticed. In its 2026 takedown announcement, the Justice Department reported that the Health Care Fraud Unit’s Data Analytics Team detected a spike in payment for allografts, leading to prosecutions — and that without CMS action, the Part B premium increase caused by allograft payments alone would have cost every Medicare beneficiary an extra $11 a month. Unusual skin substitute billing is now a signal the government actively investigates.

How Skin Substitute and Amniotic Graft Billing Fraud Works

Federal charging documents and civil resolutions describe a consistent set of patterns:

• Medically unnecessary grafts. In the 2025 takedown cases, defendants allegedly applied amniotic allografts to superficial wounds that did not need the treatment, without coordination with the patients’ treating physicians and without proper treatment for infection.
• Size and unit manipulation. In the Arizona wound graft prosecution, sales representatives were allegedly required to order only the largest sizes of grafts available; grafts were applied to areas that far exceeded the size of the wound, several grafts were applied to single wounds, and grafts were applied to non-existent wounds.
• Targeting hospice and terminally ill patients. Defendants allegedly targeted vulnerable elderly patients, many of whom were receiving hospice care. In the Arizona case, grafts were applied to terminally ill patients receiving palliative care, some of whom died within days — or the same day — of the allograft application.
• Kickbacks built into the price. In a case charged in the 2026 takedown, an allograft company allegedly acquired grafts from tissue banks and relabeled them for sale at a 2,000% mark-up, charging up to $1,450 per square centimeter, then paid illegal kickbacks of approximately 40% of that amount — letting marketers and medical providers pocket approximately $500-600 per square centimeter.
• Upcoded wound care procedures. Federal enforcers have also pursued debridement upcoding — allegations that routine, non-surgical wound management was billed to Medicare as higher-reimbursed surgical excisional debridement, with billing software configured to generate the more lucrative codes automatically.

According to the Justice Department’s December 2025 announcement in the Arizona matter, nurse practitioners were instructed to suspend their medical judgment and apply whatever quantities and sizes of grafts had been ordered by medically untrained sales representatives. If graft size, frequency, or placement at your workplace is treated as a sales decision rather than a medical one, you may be looking at the same conduct.

Recent Wound Care Enforcement: Sentences, Settlements, and New Charges

In the first prosecution of its kind, the owners of several Arizona wound graft companies were sentenced to prison terms of 15.5 years and 14 years for their roles in the scheme. Over 18 months, from November 2022 through May 2024, the defendants and their co-conspirators submitted approximately $1,212,005,778 in false and fraudulent claims, including over $960 million to Medicare, TRICARE, and CHAMPVA, and the federal and commercial programs collectively paid $614,945,420 on those claims. Every False Claims Act matter is different; results depend on the specific facts of each case, and no similar outcome is implied.

On the civil side of the same matter, one owner and her wound graft marketing company, Apex Medical LLC, agreed to pay $279,912,916, and the other owner agreed to pay $30 million, to resolve their respective liability under the False Claims Act for allegations involving medically unnecessary wound allografts and illegal kickbacks from a wholesale allograft distributor. Every False Claims Act matter is different; results depend on the specific facts of each case, and no similar outcome is implied.

That case began with insiders. The Justice Department stated that the False Claims Act allegations were originally brought by whistleblowers under the qui tam provisions, that the matters remain under seal while the investigation of other parties continues, and that the amount of the whistleblower shares had not yet been determined.

Wound care enforcement extends beyond grafts. In November 2025, Dr. Ameet Vohra and his companies, including Vohra Wound Physicians Management LLC, agreed to pay $45 million to resolve allegations that they knowingly caused Medicare to be billed for medically unnecessary surgical debridement procedures, for surgical procedures when only routine non-surgical wound management had been done, and for evaluation and management services that were not billable under Medicare coverage and coding rules. The settlement includes a five-year Corporate Integrity Agreement with HHS-OIG, and the claims resolved are allegations only, with no determination of liability. Every False Claims Act matter is different; results depend on the specific facts of each case, and no similar outcome is implied.

The 2026 takedown also charged individual providers: a nurse practitioner in the Southern District of Texas in a $906 million scheme that allegedly billed Medicare more than $1 million per patient on average for medically unnecessary allografts, and three defendants in the Middle District of Florida in an $118 million allograft fraud scheme. These are criminal charges, and the government’s descriptions of them are allegations.

CMS Changed the Payment Rules — Past Claims Still Count

Under the CY 2026 Physician Fee Schedule final rule, Medicare now pays for skin substitute products as incident-to supplies when used as part of a covered application procedure, at a single payment rate of approximately $127.28, with products categorized consistent with their FDA regulatory status.

The reform narrows the margins that fueled these schemes going forward, but it does not erase liability for claims already submitted. Under 31 U.S.C. § 3731(b), a civil action may be brought up to 6 years after the violation — or up to 3 years after the responsible United States official knew or reasonably should have known the material facts, capped at 10 years. Billing from the boom years could remain actionable well into the future.

Who Sees Wound Care Fraud First

The recent cases show who tends to be in the room when this conduct occurs:

• Wound-care nurses and nurse practitioners told to apply grafts ordered by sales staff, to use sizes that exceed the wound, or to treat hospice patients whose own physicians were never consulted.
• Sales representatives and marketers for graft manufacturers and distributors offered per-square-centimeter commissions resembling the kickback structures described in the federal takedowns.
• Billers and coders at mobile wound-care companies who see the gap between the wound measurements in the chart and the graft units billed, or who watch software convert routine care into surgical procedure codes.
• Hospice and long-term-care staff who notice outside providers applying expensive grafts to patients receiving palliative or end-of-life care.

The Qui Tam Path for a Wound Care Whistleblower

The False Claims Act imposes liability on any person who knowingly presents, or causes to be presented, a false or fraudulent claim for payment, or who knowingly makes or uses a false record or statement material to a false claim. Under 31 U.S.C. § 3729(a), a violator is liable for a civil penalty of not less than $5,000 and not more than $10,000 per claim, as adjusted by the Federal Civil Penalties Inflation Adjustment Act of 1990, plus 3 times the amount of damages the government sustains.

Under 31 U.S.C. § 3730(b), a private person may bring the civil action for the person and for the United States government, in the name of the government. The complaint is filed in camera, remains under seal for at least 60 days, and is not served on the defendant until the court so orders. The government may elect to intervene within 60 days after it receives both the complaint and the material evidence.

The statute also protects the people who come forward. Under 31 U.S.C. § 3730(h), an employee, contractor, or agent who is discharged, demoted, suspended, threatened, harassed, or otherwise discriminated against for lawful acts in furtherance of a False Claims Act action — or for other efforts to stop violations — is entitled to relief that includes reinstatement with the same seniority status, 2 times the amount of back pay, interest on the back pay, and compensation for special damages, including litigation costs and reasonable attorneys’ fees.

Price Armstrong LLC is a plaintiff-side law firm representing whistleblowers nationwide in federal False Claims Act matters, associating local counsel where required, with offices in Birmingham, Alabama; Tallahassee, Florida; and Albany, Georgia. Case evaluations are free and confidential.

If this looks familiar from your own workplace, you can discuss what you have seen with a Price Armstrong attorney confidentially and at no cost. Call (888) 670-9542 or use the secure evaluation form below.

Frequently Asked Questions

What is skin substitute fraud?

Skin substitute fraud is billing federal health care programs for skin substitutes — including amniotic membrane allografts — in ways that violate the False Claims Act. Patterns described in federal cases include grafts that are not medically necessary, graft sizes that far exceed the wound, grafts applied to non-existent wounds or to hospice patients, kickbacks tied to graft orders, and routine wound care upcoded as surgical debridement.

How much may a skin substitute fraud whistleblower receive?

Under 31 U.S.C. § 3730(d), a whistleblower whose qui tam case leads to a recovery generally receives at least 15 percent but not more than 25 percent of the proceeds if the government proceeds with the action, and not less than 25 percent and not more than 30 percent if the whistleblower litigates without government intervention, plus reasonable expenses, attorneys’ fees, and costs. Every False Claims Act matter is different; results depend on the specific facts of each case, and no similar outcome is implied.

What happens after I file a qui tam complaint?

The complaint is filed in camera and remains under seal for at least 60 days while the government investigates; it is not served on the defendant until the court so orders. The government may elect to intervene within 60 days after receiving the complaint and supporting evidence, and may seek seal extensions for good cause. The seal can last a long time: in the Arizona wound graft matter, the qui tam cases remained under seal even after the civil resolutions were announced.

Am I protected from retaliation for reporting wound care fraud?

The False Claims Act’s anti-retaliation provision, 31 U.S.C. § 3730(h), covers employees, contractors, and agents who face discharge, demotion, suspension, threats, harassment, or other discrimination for lawful acts in furtherance of a False Claims Act action or other efforts to stop violations. Relief includes reinstatement with the same seniority status, 2 times the amount of back pay, interest, and compensation for special damages, including litigation costs and reasonable attorneys’ fees.

CMS cut skin substitute payments in 2026 — is it too late to report?

The CY 2026 payment reform changed reimbursement going forward; it did not wipe out liability for claims already submitted. Under 31 U.S.C. § 3731(b), a civil action may be brought up to 6 years after a violation, or in some circumstances up to 10 years, so a large volume of billing from the boom years may still fall within the limitations period — but the first-to-file rule can bar later cases built on the same facts, so timing may matter.

Do I need medical training to be a whistleblower?

No. The qui tam provisions allow a person — not only a clinician — to bring a civil action for a violation of the False Claims Act. The wound care cases center on sales representatives, marketers, and billing operations — the people who hold the graft orders, commission structures, and claims records that can reveal a scheme.